Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: PharmaEngine, Inc.

Market Cap 8.28B 262M 225M 208M 195M 365M 24.9B 370M 2.46B 956M 12.11B 982M 961M 41.83B P/E Ratio 2024
7.42x
P/E Ratio 2025 26.2x
Enterprise Value 3.6B 114M 98.06M 90.38M 84.67M 159M 10.83B 161M 1.07B 416M 5.27B 427M 418M 18.2B EV / Sales 2024
3.61x
EV / Sales 2025 5.97x
Free-Float
61.82%
Yield 2024
6.64%
Yield 2025 2.84%
1 day+0.35%
1 week+3.78%
Current month+7.46%
1 month+2.49%
3 months+0.70%
6 months-18.18%
Current year-18.18%
1 week 53.4
Extreme 53.4
58.6
1 month 53
Extreme 53
58.6
Current year 53
Extreme 53
74
1 year 53
Extreme 53
82.5
3 years 53
Extreme 53
123
5 years 53
Extreme 53
150.5
10 years 33.1
Extreme 33.1
212.51
Manager TitleAgeSince
Chief Executive Officer - -
Director of Finance/CFO - 2021-05-16
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member - 2018-01-18
Director/Board Member - 2019-06-12
Director/Board Member - 2018-05-14
Change 5-day change 1-year change 3-year change Capi.($)
+0.35%+3.78%-28.98%-39.05% 262M
-0.35%+0.97%-13.80%-13.25% 43.03B
+3.11%+3.11%+279.08%+501.52% 32.71B
+0.22%-1.08%+15.66%-15.65% 30.29B
+1.62%-2.08%-1.91%+24.64% 29.4B
+4.09%+0.93%+12.97%+20.22% 25.08B
+1.14%+3.62% - - 13.54B
-1.63%+2.88%+56.69%+113.41% 13.35B
-0.40%-1.29%+6.23%+7.63% 12.97B
-0.74%-1.62%+105.89%+74.92% 12.11B
Average +0.74%+1.50%+47.98%+74.93% 21.27B
Weighted average by Cap. +1.05%+1.48%+57.19%+95.90%

Financials

2024 2025
Net sales 2.52B 79.82M 68.71M 63.33M 59.33M 111M 7.59B 113M 750M 291M 3.69B 300M 293M 12.75B 911M 28.83M 24.82M 22.87M 21.43M 40.22M 2.74B 40.73M 271M 105M 1.33B 108M 106M 4.61B
Net income 1.75B 55.39M 47.68M 43.95M 41.17M 77.27M 5.27B 78.25M 520M 202M 2.56B 208M 203M 8.85B 388M 12.26M 10.56M 9.73M 9.11M 17.11M 1.17B 17.32M 115M 44.76M 567M 46.01M 45.04M 1.96B
Net Debt -3.85B -122M -105M -96.72M -90.61M -170M -11.59B -172M -1.15B -445M -5.64B -457M -448M -19.48B -4.67B -148M -127M -117M -110M -206M -14.06B -209M -1.39B -540M -6.84B -555M -543M -23.63B
Logo PharmaEngine, Inc.
PharmaEngine Inc is a Taiwan-based company primarily engaged in new drug development. The main business is the research and development of various cancer drugs. ONIVYDE is a novel and stable encapsulated form of the marketed chemotherapy drug irinotecan in a long-circulating nanoliposome for the treatment of patients with metastatic adenocarcinoma of the pancreas who have been previously treated with gemcitabine-based therapy. It has received marketing approvals in Taiwan, the United States, the European Union, Singapore, South Korea, Japan, China and other regions. PEP07, a checkpoint kinase 1 (CHK1) inhibitor, which targets the deoxyribonucleic acid damage response (DDR) network, is in Phase 1 clinical trial stage and its target is to treat hematologic cancers such as acute myeloid leukemia (AML) and mantle cell lymphoma (MCL), and solid tumors.
Employees
45
Date Price Change Volume
26-06-12 57.60 NT$ +0.35% 541,412
26-06-11 57.40 NT$ +0.35% 424,726
26-06-10 57.20 NT$ +0.35% 1,264,325
26-06-09 57.00 NT$ +0.88% 634,770
26-06-08 56.50 NT$ +1.80% 693,637
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BB

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. 4162 Stock
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!